Livingston

Researchers are evaluating how well elacestrant works compared to standard endocrine therapy in adults with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer who are at high risk of the cancer returning. This is a Phase 3 global, multicenter, randomized, open-label study focusing on participants who have had early invasive breast cancer removed and meet specific receptor and risk criteria. The study aims to understand which treatment better prevents invasive breast cancer over up to five years. Participants will receive either elacestrant or one of several standard endocrine therapies, including anastrozole, letrozole, exemestane, or tamoxifen, all given as oral tablets. Treatments will be administered according to the study plan, with careful monitoring throughout the trial. The study includes adults who have already received between 24 and 60 months of prior endocrine therapy, with or without certain inhibitors, and who have completed or stopped these treatments as required. During the study, participants will be monitored for invasive breast cancer-free survival for up to five years. Researchers will perform regular assessments to track treatment effects, side effects, and cancer recurrence. The study also includes safety monitoring and may involve additional tests or evaluations as needed to ensure participant well-being throughout the trial.

The purpose of this clinical trial is to evaluate the safety and performance of the RTD Wound Dressing in the treatment of non-infected neuropathic, ischaemic, and neuro-ischaemic diabetic foot ulcers versus standard of care. This clinical evaluation study will be performed under an open-label, comparative, design in the single health board of NHS Lanarkshire within 3 diabetic foot clinics.

Patients with head and neck cancer who have undergone radiation therapy to the neck face a higher risk of difficult mask ventilation and tracheal intubation during general anesthesia. Failure to maintain proper oxygenation in these patients can cause severe brain injury or death. Current guidelines recommend using a second generation laryngeal mask airway as a rescue technique when ventilation or intubation fails, but these guidelines do not specifically address patients with irradiated necks. This research evaluates the effectiveness of the IGEL laryngeal mask airway device as a rescue tool for airway control in patients who previously received radiotherapy to the neck. The study involves inserting the IGEL device in anesthetized patients undergoing elective procedures that require general anesthesia. The focus is on assessing the device's ability to maintain ventilation in this high-risk group. Participants will be monitored for successful device insertion and ventilation within 10 minutes. Researchers will track the ease and success of airway management using the IGEL device in these patients. The study aims to provide insights into the likelihood of successful rescue ventilation in patients with irradiated necks, improving understanding of airway management in this specific population.

Researchers are evaluating the general psychiatric and medical characteristics of 100 adults admitted to NHS General Adult Psychiatry (GAP) inpatient wards. This observational study aims to provide detailed information on the health conditions and morbidity of this patient group, who often have multiple co-existing conditions and may be treatment resistant. The study will use common diagnostic tools and severity rating scales to better understand how typical GAP patients compare to participants in clinical trials, addressing why some trial results may not apply well to real-life patients. Participants will complete questionnaires, rating scales, and have their medical notes reviewed during the study. These assessments will provide detailed data about their psychiatric diagnoses, severity of symptoms such as psychosis, depression, mania, and anxiety, substance use, physical health abnormalities, and treatment resistance. The study is cross-sectional, with participants spending about an hour answering questionnaires and speaking with their clinician. The study takes place at St John's Hospital in Livingston, West Lothian, involving patients aged 18 to 65 years who have mental disorders not treated by their general practitioner. Researchers will measure many health aspects at enrollment, including psychiatric diagnoses, severity of mental health symptoms, physical illnesses, laboratory values, and legal status under the Mental Health Act. Participants can withdraw at any time, and minimal personal information will be collected to protect privacy.

Researchers are conducting a phase III, randomized, open-label, international trial to compare ruxolitinib with the best available therapy for patients with high-risk polycythemia vera (PV). The best available therapy includes either interferon alpha or hydroxycarbamide, selected by the investigator before randomization. This study aims to evaluate which treatment better prevents major complications like thrombosis, hemorrhage, or progression to more severe blood disorders within approximately three years. Participants will be randomly assigned to receive either ruxolitinib at a dose of 10 mg twice daily or best available therapy consisting of interferon alpha or hydroxycarbamide, administered through standard hospital methods. There will be no crossover between treatment arms during the trial. Interferon formulations, including pegylated-interferon, may be used at the investigator's discretion. During the study, participants will be monitored for event-free survival, defined as the time until the first major thrombosis, hemorrhage, death, or disease transformation. Assessments will include regular clinical evaluations and laboratory tests over the approximately three-year trial period. The trial emphasizes safety and effectiveness by closely observing patient outcomes and treatment tolerability throughout the study.

Researchers are evaluating whether a wrist-worn activity monitor can help healthcare professionals understand how adults recover after leaving the intensive care unit (ICU). The study focuses on adults discharged from ICUs in three hospitals in Edinburgh and aims to see if movement data collected at home can provide useful information about recovery. It also seeks to find out if changes in activity relate to symptoms like pain, anxiety, daily functioning, sleep, and cognition during the early post-ICU period. Participants wear the wrist activity monitor continuously for two months after hospital discharge while completing health-related questionnaires. They are also part of the Critical Care Recovery Service, which supports ICU survivors with physical and psychological rehabilitation. The study collects patient-reported outcomes and movement data to identify early signs of deterioration or unmet rehabilitation needs. During the two months following discharge, participants undergo structured telephone assessments to evaluate their quality of life, physical abilities, and cognitive function. Researchers monitor these data alongside continuous accelerometer readings from the wrist device to assess the feasibility of wearable data collection and its relationship with recovery measures. This study helps explore the value of combining wearable monitoring with repeated patient reports to support recovery after critical illness.